Nyxoah S.A. (NYXH): Business Model Canvas [Jan-2025 Updated]

Imagine a groundbreaking medical technology that could revolutionize sleep apnea treatment, offering patients a non-invasive solution that transforms nighttime struggles into peaceful rest. Nyxoah S.A. (NYXH) is pioneering a neurostimulation platform that challenges traditional sleep disorder management, promising minimally invasive treatments that could dramatically improve patient quality of life. This innovative company is not just developing a medical device; they're reimagining how we approach sleep health, combining cutting-edge technology with a deep understanding of patient needs and medical challenges.

Nyxoah S.A. (NYXH) - Business Model: Key Partnerships

Medical Device Manufacturers for Component Sourcing

Nyxoah collaborates with specific medical device component manufacturers:

Manufacturer	Component Type	Relationship Status
Medtronic Inc.	Neurostimulation Components	Active Partnership
Zimmer Biomet	Precision Electronic Interfaces	Strategic Supplier

Sleep Clinics and Sleep Disorder Research Centers

Key research and clinical partnerships include:

• Johns Hopkins University Sleep Center
• Stanford Sleep Medicine Center
• University of Pennsylvania Sleep Research Laboratory

Healthcare Technology Investors and Venture Capital Firms

Investor	Investment Amount	Investment Year
Sofinnova Partners	€15.2 million	2022
Bpifrance	€8.7 million	2021

Regulatory Bodies

Regulatory compliance partnerships:

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Belgian Federal Agency for Medicines and Health Products

Academic Medical Institutions

Institution	Research Focus	Collaboration Status
KU Leuven	Neurostimulation Technologies	Ongoing Clinical Research
Université Libre de Bruxelles	Sleep Disorder Interventions	Research Partnership

Nyxoah S.A. (NYXH) - Business Model: Key Activities

Developing Innovative Sleep Apnea Treatment Technologies

Nyxoah S.A. focuses on developing the Genio® system, a neurostimulation device for obstructive sleep apnea (OSA) treatment. As of 2023, the company invested €12.9 million in research and development.

Technology Development Metrics	2023 Data
R&D Expenditure	€12.9 million
Patent Applications	7 active patents
Technology Iterations	3 major device generations

Conducting Clinical Trials for Medical Device Efficacy

Nyxoah has conducted multiple clinical trials to validate the Genio® system's effectiveness.

• DREAM IDE clinical study completed with 117 patients
• European clinical trials covering 5 countries
• FDA approval process ongoing

Manufacturing Minimally Invasive Neurostimulation Devices

The company manufactures the Genio® system with precision engineering and strict quality controls.

Manufacturing Metrics	2023 Data
Annual Production Capacity	5,000 devices
Manufacturing Locations	Belgium and contract manufacturing partners
Quality Control Compliance	ISO 13485 certified

Pursuing Regulatory Approvals in Multiple Markets

Nyxoah actively seeks regulatory approvals across different geographic markets.

• CE Mark obtained in Europe in 2019
• FDA Breakthrough Device Designation received
• Ongoing regulatory submissions in United States and Asia

Continuous Research and Development in Sleep Disorder Solutions

Nyxoah continues investing in advanced sleep disorder treatment technologies.

R&D Focus Areas	2023-2024 Investment
Sleep Apnea Technology	€8.5 million
Next-Generation Device Development	€3.2 million
Clinical Research	€1.2 million

Nyxoah S.A. (NYXH) - Business Model: Key Resources

Proprietary Neurostimulation Technology Platform

Nyxoah's key technology platform is the Genio® system, a leadless, battery-less neurostimulation device for treating obstructive sleep apnea (OSA).

Technology Specification	Details
Device Type	Implantable neurostimulation system
CE Mark Approval	Received in 2019
Current Generation	Genio® Gen2

Specialized Medical Engineering and Research Talent

Nyxoah's human resources include:

• Total employees as of 2023: 85
• R&D team composition: 40% of total workforce
• Advanced degrees among staff: 65% with PhD or Master's

Intellectual Property Portfolio and Medical Device Patents

Patent Category	Number of Patents
Total Patent Families	25
Active Patents	18
Pending Patent Applications	7

Advanced Manufacturing Facilities

Nyxoah utilizes contract manufacturing partners with specialized medical device production capabilities.

• Primary Manufacturing Location: Belgium
• ISO 13485 Certified Production Processes
• Annual Production Capacity: 5,000 devices

Clinical Trial Data and Research Expertise

Clinical Trial Metrics	Quantitative Data
Completed Clinical Trials	4
Total Patient Participants	250+
Published Research Papers	12

Nyxoah S.A. (NYXH) - Business Model: Value Propositions

Non-invasive Treatment for Obstructive Sleep Apnea

Nyxoah's Genial® System offers a non-surgical alternative for treating obstructive sleep apnea (OSA). The device provides a solution with the following key specifications:

Device Specification	Value
Weight	3 grams
Implant Depth	Less than 1 mm under tongue
Battery Life	Rechargeable daily

Improved Patient Comfort

Compared to traditional CPAP devices, Nyxoah's solution offers superior comfort:

• No facial masks required
• Minimal device visibility
• Unrestricted sleep positions

Potential Reduction in Sleep Apnea Health Complications

Clinical data demonstrates significant improvements:

Health Metric	Improvement Percentage
Apnea-Hypopnea Index (AHI)	Reduction of 78%
Oxygen Desaturation	Decreased by 68%

Personalized and Adaptive Sleep Disorder Management

The Genial® System provides personalized therapy through:

• Real-time sleep pattern monitoring
• Adaptive stimulation technology
• Remote tracking capabilities

Minimal Surgical Intervention Required

Surgical procedure specifications:

Surgical Aspect	Details
Procedure Duration	Approximately 30 minutes
Anesthesia Type	Local or light sedation
Recovery Time	Typically 24-48 hours

Nyxoah S.A. (NYXH) - Business Model: Customer Relationships

Direct Medical Professional Engagement

Nyxoah collaborates with sleep specialists and ENT surgeons through targeted medical education programs. In 2023, the company engaged with 327 sleep medicine professionals across Europe and the United States.

Engagement Type	Number of Professionals	Geographic Reach
Sleep Medicine Specialists	224	Europe
ENT Surgeons	103	United States

Technical Support for Device Implementation

Nyxoah provides comprehensive technical support for its Genio® system implementation.

• 24/7 technical support hotline
• Dedicated implementation training for medical professionals
• Remote device configuration assistance

Ongoing Patient Monitoring and Follow-up Services

The company offers structured patient monitoring protocols with real-time data tracking. In 2023, Nyxoah monitored 642 patients across clinical implementation sites.

Monitoring Parameter	Tracking Frequency	Data Points Collected
Sleep Apnea Metrics	Monthly	AHI, Oxygen Saturation
Device Performance	Quarterly	Battery Life, Usage Hours

Digital Health Platform for Patient Tracking

Nyxoah's digital platform enables remote patient monitoring with secure cloud-based data management. Platform statistics for 2023:

• Platform Users: 512
• Data Security Compliance: HIPAA, GDPR
• Average Monthly Active Users: 387

Educational Resources About Sleep Disorder Management

Nyxoah provides comprehensive educational materials for patients and healthcare providers.

Resource Type	Number of Materials	Distribution Channels
Patient Guides	24	Website, Medical Clinics
Professional Training Modules	12	Online Platforms, Conferences

Nyxoah S.A. (NYXH) - Business Model: Channels

Direct Sales to Sleep Clinics and Hospitals

Nyxoah S.A. directly targets sleep clinics and hospitals through specialized medical sales representatives. In 2023, the company reported direct sales engagement with 127 specialized sleep centers across Europe.

Region	Number of Direct Sales Contacts	Penetration Rate
Europe	127	62%
United States	48	35%

Medical Device Distribution Networks

Nyxoah utilizes specialized medical device distribution networks to expand its market reach.

• Active distribution partnerships with 14 medical device distributors
• Coverage across 6 European countries
• Distribution network revenue: €3.2 million in 2023

Online Medical Technology Platforms

The company leverages digital platforms for product information and medical professional engagement.

Digital Platform	Monthly Unique Visitors	Professional Registrations
Nyxoah Professional Portal	4,237	1,582

Medical Conferences and Healthcare Exhibitions

Nyxoah actively participates in medical conferences to showcase its innovative sleep technology solutions.

• Attended 23 international medical conferences in 2023
• Total conference engagement: 1,456 medical professionals
• Conference-generated leads: 412

Telemedicine and Digital Health Engagement

Digital health platforms represent an emerging channel for Nyxoah's market expansion.

Digital Health Metric	2023 Performance
Telemedicine Platform Users	2,873
Digital Patient Consultations	1,647
Digital Health Revenue	€1.1 million

Nyxoah S.A. (NYXH) - Business Model: Customer Segments

Sleep Disorder Patients

Nyxoah targets patients with Obstructive Sleep Apnea (OSA).

Patient Demographics	Statistical Data
Global OSA Prevalence	936 million individuals affected worldwide in 2022
Undiagnosed OSA Cases	80% of moderate to severe cases remain undiagnosed
Age Group Most Affected	45-65 years old

Sleep Medicine Specialists

Primary medical professionals targeted for Nyxoah's technology adoption.

• Sleep Physicians
• Pulmonologists
• ENT Specialists
• Neurologists

Healthcare Institutions

Institution Type	Potential Market Penetration
Sleep Clinics	3,500 specialized centers in North America
Hospitals	1,200 potential institutional customers in Europe
Research Centers	450 specialized sleep research facilities globally

Insurance Providers

Target segment for reimbursement and coverage of sleep apnea treatments.

Insurance Category	Market Potential
Private Health Insurance	72% coverage potential for innovative sleep technologies
Public Healthcare Systems	58% adoption rate for advanced medical devices

Aging Population with Sleep-Related Health Issues

Demographic Segment	Statistical Information
Global Population 65+ Years	9.3% in 2022, projected 16% by 2050
OSA Prevalence in Elderly	60-70% of individuals over 65 years
Chronic Condition Correlation	85% of elderly OSA patients have comorbidities

Nyxoah S.A. (NYXH) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2022, Nyxoah S.A. reported research and development expenses of €8.9 million, representing a 33% increase from €6.7 million in 2021.

Year	R&D Expenses (€)	Percentage Increase
2021	6.7 million	-
2022	8.9 million	33%

Clinical Trial Investments

Nyxoah invested €4.5 million in clinical trials during 2022, focusing on the development of its Genio® system for obstructive sleep apnea treatment.

Manufacturing and Production Costs

Manufacturing costs for the Genio® system in 2022 were approximately €3.2 million, with key components including:

• Raw material procurement: €1.1 million
• Production equipment: €0.8 million
• Manufacturing labor: €1.3 million

Regulatory Compliance and Certification

Compliance expenses for 2022 totaled €1.6 million, covering:

• FDA approval processes
• CE marking maintenance
• Quality management systems

Marketing and Sales Infrastructure

Marketing Expense Category	Amount (€)
Sales personnel	2.3 million
Digital marketing	0.7 million
Conference and event participation	0.5 million
Marketing materials	0.3 million

Total Cost Structure for 2022: Approximately €20.5 million

Nyxoah S.A. (NYXH) - Business Model: Revenue Streams

Medical Device Sales

Nyxoah generates revenue through sales of its Genio™ neurostimulation device for obstructive sleep apnea treatment. As of 2023 financial reports, the company reported €3.2 million in total revenue.

Product	Average Selling Price	Annual Sales Volume
Genio™ Device	€4,500 - €5,500	Approximately 250-300 units

Recurring Revenue from Device Replacements

The Genio™ system requires periodic replacements, creating a sustainable revenue stream.

• Device replacement cycle: Approximately every 3-4 years
• Estimated replacement revenue per device: €3,000 - €4,000

Licensing of Neurostimulation Technology

Nyxoah has potential licensing opportunities for its proprietary neurostimulation technology.

Licensing Category	Potential Annual Revenue
Technology Licensing	€500,000 - €1.5 million

Reimbursement from Healthcare Insurance Providers

Nyxoah secures revenue through healthcare insurance reimbursements in multiple markets.

• Reimbursement rates: 70-90% in European markets
• Average reimbursement per procedure: €3,200 - €4,500

International Market Expansion

Nyxoah's revenue growth strategy focuses on expanding into new geographical markets.

Market	Potential Market Penetration	Estimated Additional Revenue
United States	5-10% market share	€8-12 million annually
European Expansion	Additional 3-5 countries	€5-7 million annually